drugset / Trial / NCT04744051

ATCell™ Expanded Autologous, Adipose-Derived Mesenchymal Stem Cells Deployed Via Intravenous Infusion

NCT04744051

Phase 1 Unknown 20 enrolled American CryoStem Corporation
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a Phase 1 Clinical Safety Study intended to provide preliminary assessments of the safety, tolerability, and clinical alleviation of symptoms associated with Post Concussion Syndrome (PCS), also known as Chronic Concussive Syndrome (CCS).

Timeline

Start
2021-02-01
Primary completion
2023-09-30
Completion
2024-01-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Autologous adipose-derived mesenchymal stem cells Cell therapy 5e+07 cells Intravenous
Comparator Autologous adipose-derived mesenchymal stem cells Cell therapy 1.5e+08 cells Intravenous
Comparator Autologous adipose-derived mesenchymal stem cells Cell therapy 3e+08 cells Intravenous